FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283389158> ?p ?o ?g. }

• W4283389158 endingPage "120" @default.
• W4283389158 startingPage "119" @default.
• W4283389158 abstract "Background: Peripheral T cell lymphoma (PTCL) is a group of heterogeneous T cell lymphomas. Patients who relapse from or are refractory to 1st line therapy face dismal prognosis. The response rates to commonly used 2nd line agents such as histone deacetylase inhibitors are below 30%. Immunotherapies, such as anti-PD1 antibodies, may induce hyperprogression in certain PTCL subtypes. Hence, r/r PTCL patients urgently need better therapies. Aims: Preclinical data shows JAK/STAT pathway may mediate the pathogenesis of PTCL, making it a promising target. Golidocitinib (DZD4205) is an orally available, potent, JAK1 specific inhibitor, demonstrating profound anti-tumor activities in T lymphoma cells in vitro and tumor xenograft in vivo. Here we report the preliminary data from an ongoing phase I/II study (NCT04105010) of Golidocitinib in r/r PTCL. Methods: The study included two parts: Part A (dose escalation) and Part B (dose expansion). In Part A, patients with r/r PTCL were enrolled and received Golidocitinib at different doses (150 mg or 250 mg, QD) to determine the recommended phase II dose (RP2D). Evaluation of safety and efficacy were performed by investigators per CTCAE and Lugano criteria, respectively. Part B is a single-arm, pivotal study, where patients with r/r PTCL will receive Golidocitinib at the RP2D till disease progression or intolerance. Results: As of May 31, 2021, a total of 51 patients enrolled in Part A and received Golidocitinib at 150 mg (n = 35) or 250 mg (n = 16). Patient characteristics: median age (range): 61.0 years (29-79); median prior systemic therapies (range): 2 lines (1-8). Ten patients (19.6%) had undergone hematopoietic stem cell transplantation. Fifteen patients (29.4%) had bone marrow involvement at baseline. Histological subtypes included PTCL-NOS (41.2%), AITL (39.2%), ALCL ALK- (7.8%), NKTCL (7.8%), and MEITL (3.9%). At the data cut-off (DCO), 49 patients completed at least one post-treatment Lugano assessment, of whom 21 (42.9%) achieved tumor response, including 11 complete responses (CRs, 22.4%) and 10 partial responses (20.4%). Tumor response was observed in various subtypes, including AITL (13/20), PTCL-NOS (5/19), ALCL ALK- (2/4) and NKTCL (1/4). At the DCO, the median duration of response (DoR) was not reached, and the longest DoR was > 14 months. Forty-eight patients (94.1%) experienced treatment emergent adverse events (TEAEs), of whom 30 (58.8%) experienced ≥ grade 3 TEAEs. Per investigators’ assessment, 20 patients (39.2%) experienced ≥ grade 3 TEAEs possibly related to the drug. The most common (≥ 10%) ≥ grade 3 TEAEs were neutropenia (29.4%), thrombocytopenia (15.7%) and pneumonia (11.8%). The majority of TEAEs were reversible or clinically manageable with dose modifications. Image:Summary/Conclusion: Golidocitinib shows good safety and promising anti-tumor efficacy in r/r PTCL, indicating its potential as a therapeutic option for this unmet medical need." @default.
• W4283389158 created "2022-06-25" @default.
• W4283389158 creator A5004358361 @default.
• W4283389158 creator A5006836935 @default.
• W4283389158 creator A5007428480 @default.
• W4283389158 creator A5008182205 @default.
• W4283389158 creator A5012187284 @default.
• W4283389158 creator A5017743220 @default.
• W4283389158 creator A5019659276 @default.
• W4283389158 creator A5020889106 @default.
• W4283389158 creator A5021991211 @default.
• W4283389158 creator A5028088359 @default.
• W4283389158 creator A5030344992 @default.
• W4283389158 creator A5030781801 @default.
• W4283389158 creator A5039063318 @default.
• W4283389158 creator A5050488255 @default.
• W4283389158 creator A5051273597 @default.
• W4283389158 creator A5058598303 @default.
• W4283389158 creator A5063382829 @default.
• W4283389158 creator A5066121515 @default.
• W4283389158 creator A5076088179 @default.
• W4283389158 creator A5091184427 @default.
• W4283389158 date "2022-06-01" @default.
• W4283389158 modified "2023-10-14" @default.
• W4283389158 title "S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA" @default.
• W4283389158 doi "https://doi.org/10.1097/01.hs9.0000843764.15785.8c" @default.
• W4283389158 hasPublicationYear "2022" @default.
• W4283389158 type Work @default.
• W4283389158 citedByCount "0" @default.
• W4283389158 crossrefType "journal-article" @default.
• W4283389158 hasAuthorship W4283389158A5004358361 @default.
• W4283389158 hasAuthorship W4283389158A5006836935 @default.
• W4283389158 hasAuthorship W4283389158A5007428480 @default.
• W4283389158 hasAuthorship W4283389158A5008182205 @default.
• W4283389158 hasAuthorship W4283389158A5012187284 @default.
• W4283389158 hasAuthorship W4283389158A5017743220 @default.
• W4283389158 hasAuthorship W4283389158A5019659276 @default.
• W4283389158 hasAuthorship W4283389158A5020889106 @default.
• W4283389158 hasAuthorship W4283389158A5021991211 @default.
• W4283389158 hasAuthorship W4283389158A5028088359 @default.
• W4283389158 hasAuthorship W4283389158A5030344992 @default.
• W4283389158 hasAuthorship W4283389158A5030781801 @default.
• W4283389158 hasAuthorship W4283389158A5039063318 @default.
• W4283389158 hasAuthorship W4283389158A5050488255 @default.
• W4283389158 hasAuthorship W4283389158A5051273597 @default.
• W4283389158 hasAuthorship W4283389158A5058598303 @default.
• W4283389158 hasAuthorship W4283389158A5063382829 @default.
• W4283389158 hasAuthorship W4283389158A5066121515 @default.
• W4283389158 hasAuthorship W4283389158A5076088179 @default.
• W4283389158 hasAuthorship W4283389158A5091184427 @default.
• W4283389158 hasBestOaLocation W42833891581 @default.
• W4283389158 hasConcept C121332964 @default.
• W4283389158 hasConcept C126322002 @default.
• W4283389158 hasConcept C142424586 @default.
• W4283389158 hasConcept C143998085 @default.
• W4283389158 hasConcept C203014093 @default.
• W4283389158 hasConcept C2776090121 @default.
• W4283389158 hasConcept C2777891184 @default.
• W4283389158 hasConcept C2779338263 @default.
• W4283389158 hasConcept C71924100 @default.
• W4283389158 hasConcept C87355193 @default.
• W4283389158 hasConcept C8891405 @default.
• W4283389158 hasConcept C90924648 @default.
• W4283389158 hasConceptScore W4283389158C121332964 @default.
• W4283389158 hasConceptScore W4283389158C126322002 @default.
• W4283389158 hasConceptScore W4283389158C142424586 @default.
• W4283389158 hasConceptScore W4283389158C143998085 @default.
• W4283389158 hasConceptScore W4283389158C203014093 @default.
• W4283389158 hasConceptScore W4283389158C2776090121 @default.
• W4283389158 hasConceptScore W4283389158C2777891184 @default.
• W4283389158 hasConceptScore W4283389158C2779338263 @default.
• W4283389158 hasConceptScore W4283389158C71924100 @default.
• W4283389158 hasConceptScore W4283389158C87355193 @default.
• W4283389158 hasConceptScore W4283389158C8891405 @default.
• W4283389158 hasConceptScore W4283389158C90924648 @default.
• W4283389158 hasLocation W42833891581 @default.
• W4283389158 hasLocation W42833891582 @default.
• W4283389158 hasOpenAccess W4283389158 @default.
• W4283389158 hasPrimaryLocation W42833891581 @default.
• W4283389158 hasRelatedWork W2033893063 @default.
• W4283389158 hasRelatedWork W2068316626 @default.
• W4283389158 hasRelatedWork W2110818089 @default.
• W4283389158 hasRelatedWork W2351796763 @default.
• W4283389158 hasRelatedWork W2351985199 @default.
• W4283389158 hasRelatedWork W2403502999 @default.
• W4283389158 hasRelatedWork W2567738959 @default.
• W4283389158 hasRelatedWork W3180188719 @default.
• W4283389158 hasRelatedWork W4297834875 @default.
• W4283389158 hasRelatedWork W4366141624 @default.
• W4283389158 hasVolume "6" @default.
• W4283389158 isParatext "false" @default.
• W4283389158 isRetracted "false" @default.
• W4283389158 workType "article" @default.